請輸入關鍵字
請輸入關鍵字
訂購
*國家
中國
美國
中國香港
中國澳門
中國台灣
阿爾巴尼亞
阿爾及利亞
阿根廷
阿拉伯聯合酋長國
阿魯巴
阿曼
阿塞拜疆
阿森鬆島
埃及
埃塞俄比亞
愛爾蘭
愛沙尼亞
安道爾
安哥拉
安圭拉
安提瓜和巴布達
奧地利
奧蘭群島
澳大利亞
巴巴多斯
巴布亞新幾內亞
巴哈馬
巴基斯坦
巴拉圭
巴勒斯坦領土
巴林
巴拿馬
巴西
白俄羅斯
百慕大
保加利亞
北馬裏亞納群島
貝寧
比利時
冰島
波多黎各
波蘭
波斯尼亞和黑塞哥維那
玻利維亞
伯利茲
博茨瓦納
不丹
布基納法索
布隆迪
朝鮮
赤道幾內亞
丹麥
德國
迪戈加西亞島
東帝汶
多哥
多米尼加共和國
多米尼克
俄羅斯
厄瓜多爾
厄立特裏亞
法國
法羅群島
法屬波利尼西亞
法屬圭亞那
法屬南部領地
梵蒂岡
菲律賓
斐濟
芬蘭
佛得角
福克蘭群島
岡比亞
剛果(布)
剛果(金)
哥倫比亞
哥斯達黎加
格恩西島
格林納達
格陵蘭
格魯吉亞
古巴
瓜德羅普
關島
圭亞那
哈薩克斯坦
海地
韓國
荷蘭
荷屬加勒比區
荷屬聖馬丁
黑山
洪都拉斯
基裏巴斯
吉布提
吉爾吉斯斯坦
幾內亞
幾內亞比紹
加拿大
加納
加納利群島
加蓬
柬埔寨
捷克
津巴布韋
喀麥隆
卡塔爾
開曼群島
科科斯(基林)群島
科摩羅
科索沃
科特迪瓦
科威特
克羅地亞
肯尼亞
庫克群島
庫拉索
拉脫維亞
萊索托
老撾
黎巴嫩
立陶宛
利比裏亞
利比亞
聯合國
列支敦士登
留尼汪
盧森堡
盧旺達
羅馬尼亞
馬達加斯加
馬恩島
馬爾代夫
馬耳他
馬拉維
馬來西亞
馬裏
馬其頓
馬紹爾群島
馬提尼克
馬約特
毛裏求斯
毛裏塔尼亞
美國本土外小島嶼
美屬薩摩亞
美屬維爾京群島
蒙古
蒙特塞拉特
孟加拉國
秘魯
密克羅尼西亞
緬甸
摩爾多瓦
摩洛哥
摩納哥
莫桑比克
墨西哥
納米比亞
南非
南極洲
南喬治亞和南桑威奇群島
南蘇丹
瑙魯
尼加拉瓜
尼泊爾
尼日爾
尼日利亞
紐埃
挪威
諾福克島
帕勞
皮特凱恩群島
葡萄牙
日本
瑞典
瑞士
薩爾瓦多
薩摩亞
塞爾維亞
塞拉利昂
塞內加爾
塞浦路斯
塞舌爾
沙特阿拉伯
聖巴泰勒米
聖誕島
聖多美和普林西比
聖赫勒拿
聖基茨和尼維斯
聖盧西亞
聖馬丁島
聖馬力諾
聖皮埃爾和密克隆群島
聖文森特和格林納丁斯
斯裏蘭卡
斯洛伐克
斯洛文尼亞
斯瓦爾巴和揚馬延
斯威士蘭
蘇丹
蘇裏南
所羅門群島
索馬裏
塔吉克斯坦
泰國
坦桑尼亞
湯加
特克斯和凱科斯群島
特裏斯坦-達庫尼亞群島
特立尼達和多巴哥
突尼斯
圖瓦盧
土耳其
土庫曼斯坦
托克勞
瓦利斯和富圖納
瓦努阿圖
危地馬拉
委內瑞拉
文萊
烏幹達
烏克蘭
烏拉圭
烏茲別克斯坦
希臘
西班牙
西撒哈拉
新加坡
新喀裏多尼亞
新西蘭
匈牙利
休達及梅利利亞
敘利亞
牙買加
亞美尼亞
也門
伊拉克
伊朗
以色列
意大利
印度
印度尼西亞
英國
英屬維爾京群島
英屬印度洋領地
約旦
越南
讚比亞
澤西島
乍得
直布羅陀
智利
中非共和國
*省份
*城市
*姓名
*電話
*單位
*職位
*郵箱
*請輸入驗證碼
*驗證碼
B-hPD-1/hPD-L1/hSIRPA/hCD47 mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Cd274tm1(CD274)Bcgen Sirpatm1(SIRPA)Bcgen Cd47tm1(CD47)Bcgen/Bcgen
Common Name  B-hPD-1/hPD-L1/hSIRPA/hCD47 mice
Background C57BL/6 Catalog number  140577
Aliases
CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, Hsle1, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1, B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2, bA574F11.2,BIT, CD172A, MFR, MYD-1, P84, PTPNS1, SHPS1, SIRP, IAP, MER6, OA3
NCBI Gene ID
18566,60533,19261,16423

Protein expression analysis

from clipboard


Strain specific PD-1, PD-L1, CD47 and SIRPα expression analysis in homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice by flow cytometry. Splenocytes from both wild type (+/+) C57BL/6  and  homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 (H/H) mice were analyzed by flow cytometry. Mouse PD-1+, PD-L1 and CD47+ T cells were only detectable in the WT C57BL/6 mice. Human PD-1+, PD-L1+ and CD47+ T cells were  only detectable in the homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Mouse SIRPα was detectable in WT mice. This anti-mouse SIRPα antibody also cross reacts with hSIRPα. Human SIRPα was exclusively detectable in homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice but not in WT mice.

Protein expression analysis

from clipboard

Strain specific PD-1, PD-L1, CD47 and SIRPα expression analysis in homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice by flow cytometry. Splenocytes from both wild type (+/+) C57BL/6  and  homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 (H/H) mice were stimulated with anti-CD3ε in vivo and analyzed by flow cytometry. Mouse PD-1+, PD-L1 and CD47+ T cells were only detectable in the WT C57BL/6 mice.  Human PD-1+, PD-L1+ and CD47+ T cells were  only detectable in the homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Mouse SIRPα was detectable in WT mice. This anti-mouse SIRPα antibody also cross reacts with hSIRPα. Human SIRPα was exclusively detectable in homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice but not in WT mice.

Analysis of spleen leukocytes cell subpopulations in B-hPD-1/hPD-L1/hSIRPA/hCD47

from clipboard


from clipboard


Analysis of spleen leukocyte subpopulations by FACS
Splenocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hSIRPA/hCD47 (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for CD45 population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, monocytes, DCs, granulocytes and macrophages in homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 were similar to those in the C57BL/6 mice, demonstrating that introduction of hSIRPα and hCD47 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

Analysis of spleen T cell subpopulations in B-hPD-1/hPD-L1/hSIRPA/hCD47a

from clipboard


Analysis of spleen T cell subpopulations by FACS
Splenocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hSIRPA/hCD47 mice (n=3, 6-week-old).  Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of  hSIRPα and hCD47 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.

Analysis of lymph node T cell subpopulations in B-hPD-1/hPD-L1/hSIRPA/hCD47



from clipboard


Analysis of lymph node T cell and NK cell subpopulations by FACS
Lymphocyte were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hSIRPA/hCD47 mice (n=3, 6-week-old).  Flow cytometry analysis of the lymphocyte was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, NK and Treg cells in homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of  hPD-1, hPD-L1, hSIRPα and hCD47 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.

Blood routine test of B-hPD-1/hPD-L1/hSIRPA/hCD47 mice

from clipboard


Complete blood count (CBC) 
Blood from female C57BL/6 and B-hPD-1/hPD-L1/hSIRPA/hCD47 mice (n=5, 6 weeks-old) was collected and analyzed by CBC. Except PLT, RBC, Hb and HCT, C57BL/6 and B-hPD-1/hPD-L1/hSIRPA/hCD47 mice showed no difference in other test results. Values are expressed as mean ± SEM.

Blood chemistry of B-hPD-1/hPD-L1/hSIRPA/hCD47 mice

from clipboard


Blood chemistry tests of B-hPD-1/hPD-L1/hSIRPA/hCD47 mice
Serum from the C57BL/6 and B-hPD-1/hPD-L1/hSIRPA/hCD47 (n=3, 6 week-old) was collected and analyzed for levels of biochemistry. There was no differences on AST, ALB, CHOL, CREA measurement between C57BL/6 and B-hPD-1/hPD-L1 mice. Values are expressed as mean ± SEM.

Combination therapy of anti-human PD-1 Ab and CD47 Ab

from clipboard

Antitumor activity of anti-human PD-1 antibody pembrolizumab (in house) combined with anti-human CD47 antibody Hu5F9 (in house) in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. (A) Pembrolizumab combined with Hu5F9 inhibited MC38-hPD-L1/hCD47 tumor growth in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Murine colon cells (5E5) were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice  (female, 8week-old, n=5). Mice were grouped when tumor volume reached approximately 150 mm3, at which time they were treated with antibodies with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of pembrolizumab and Hu5F9 shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hSIRPA/hCD47 mice provide a powerful preclinical model for in vivo evaluation of combination therapy of anti-human PD-1 and anti-human CD47 antibodies. Values are expressed as mean ± SEM. 


Combination therapy of anti-human PD-L1 Ab and CD47 Ab

from clipboard

Antitumor activity of anti-human PD-L1 antibody Atezolizumab (in house) combined with anti-human CD47 antibody Hu5F9 (in house) in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. (A) Atezolizumab combined with Hu5F9 inhibited MC38-hPD-L1/hCD47 tumor growth in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Murine colon cells (5E5) were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice  (female, 8week-old, n=5). Mice were grouped when tumor volume reached approximately 150 mm3, at which time they were treated with antibodies with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of Atezolizumab and Hu5F9 shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hSIRPA/hCD47 mice provide a powerful preclinical model for in vivo evaluation of combination therapy of anti-human PD-L1 and anti-human CD47 antibodies. Values are expressed as mean ± SEM. 


Combination therapy of anti-human PD-1 Ab and CD47 Ab

from clipboard

Antitumor activity of anti-human PD-1 antibody combined with anti-human CD47 antibody in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. (A) Anti-human PD-1 antibody combined with anti-human CD47 antibody inhibited MC38-hPD-L1/hCD47 tumor growth in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Murine colon cells (2E5) were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice  (female, 6-8 week-old, n=8). Mice were grouped when tumor volume reached 50-80 mm3, at which time they were treated with antibodies with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of anti-PD-1 and anti-CD47 shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hSIRPA/hCD47 mice provide a powerful preclinical model for in vivo evaluation of combination therapy of anti-human PD-1 and anti-human CD47 antibodies. Values are expressed as mean ± SEM. PD-1 Ab and CD47 Ab are both provided by the clients)